Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 12,550 KRW
Change Today +50.00 / 0.40%
Volume 279.0K
009290 On Other Exchanges
Korea SE
As of 2:22 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

kwang dong pharmaceutical co (009290) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/15 - 19,100
52 Week Low
10/8/14 - 9,250
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KWANG DONG PHARMACEUTICAL CO (009290)

Related News

No related news articles were found.

kwang dong pharmaceutical co (009290) Related Businessweek News

No Related Businessweek News Found

kwang dong pharmaceutical co (009290) Details

Kwang Dong Pharmaceutical Co., Ltd. researches and develops over the counter and prescription drugs in South Korea. The company offers health drinks, tea drinks, juice drinks, energy drinks, etc. It also provides products in the therapeutic areas of gastrointestinal, cardiovascular and hematopoietic, respiratory, central nervous, musculo skeletal, endocrine and metabolic, allergy and immune systems, as well as anti infective, oncology, anesthetics, vitamin/mineral, mouth/throat, dermatology, and miscellaneous products. In addition, the company operates Kwang Dong Oriental Hospital, which provides medical services. Further, it is involved in retailing and wholesaling its products to drug stores and convenient stores, as well as selling its products through TV home shopping program and Internet shopping mall. The company was founded in 1963 and is headquartered in Seoul, South Korea.

Founded in 1963

kwang dong pharmaceutical co (009290) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kwang dong pharmaceutical co (009290) Key Developments

Orexigen Therapeutics Ireland Ltd. Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical Co., Ltd

Orexigen Therapeutics Ireland Ltd. and Kwang Dong Pharmaceutical Company, Ltd. have executed a distributorship agreement for South Korea for Contrave® (naltrexone HCl /bupropion HCl extended release) monotherapy for weight management in overweight or obese adult patients. Under the terms of the agreement, Kwang Dong will be responsible for seeking regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Kwang Dong for a $7 million upfront payment, approximately 35 – 40% of net sales, potential sales-based milestone payments, and other fees. Kwang Dong expects to begin marketing Contrave in the second half of 2016, if regulatory approval is obtained. Obesity and related comorbidities are a serious health problem in South Korea, where approximately 38% of men and 26% of women are obese according to recent statistics from the National Health Institute. In 2014, sales of anti-obesity prescription medicines exceeded $67 million in Korea.

Kwang Dong Pharmaceutical Announces Promotion of Choi Sung-Wonchoi Sung-Won to Vice Chairman

Choi Sung-wonChoi Sung-won, president and CEO of Kwang Dong Pharmaceutical Co., was promoted to vice chairman. Choi, 45, has served as CEO of Kwang Dong since July 2013 when his father Choi Soo-boo, founder and chairman of the drug manufacturer, died at the age of 77. He plans to transform the company into Korea's leading healthcare provider, with the goal of generating 1 trillion won ($910 million) in sales by 2020.

Kwang Dong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2015

Kwang Dong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2015., at 09:30 Korea Standard Time. Location: Seocho-gu, Seoul in gangnamdae 27. Agenda: To consider business report, external audit reports, and the consolidated financial statements of 2014; to consider some changes in Articles of Incorporation; to consider approval of remuneration ceiling bill; to consider approval of Audit Fees limit; and to consider executive severance pay provisions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
009290:KS 12,550.00 KRW +50.00

009290 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 009290.
View Industry Companies

Industry Analysis


Industry Average

Valuation 009290 Industry Range
Price/Earnings 12.5x
Price/Sales 0.7x
Price/Book 1.4x
Price/Cash Flow 15.1x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KWANG DONG PHARMACEUTICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at